Quarterly ResultAug 5, 2026, 04:04 PM
Editas Medicine Q2 Net Loss $18.2M; EDIT-401 on track for CTN
AI Summary
Editas Medicine reported a significantly reduced net loss of $18.2 million, or $0.15 per share, for the second quarter of 2026, an improvement from $53.2 million in the prior year. The company also provided positive updates on its EDIT-401 program, including strong preclinical data showing significant reductions in atherogenic lipoproteins and plans for a Clinical Trial Notification submission this month. A recent public offering raised $125.0 million, bolstering the company's cash position to $211.6 million and extending its cash runway into the second half of 2028.
Key Highlights
- Net loss for Q2 2026 significantly improved to $18.2 million, down from $53.2 million in Q2 2025.
- Net loss per share was $0.15 for Q2 2026, compared to $0.63 per share in Q2 2025.
- Collaboration and other R&D revenues increased to $11.9 million in Q2 2026 from $3.6 million in Q2 2025.
- EDIT-401 preclinical data showed ~90% or greater mean reduction in multiple atherogenic lipoproteins in NHPs.
- Company is on track to submit a Clinical Trial Notification (CTN) for EDIT-401 this month.
- Public offering of common stock and warrants completed in May, raising $125.0 million gross proceeds.
- Cash and cash equivalents were $211.6 million as of June 30, 2026, up from $146.6 million at year-end 2025.
- Cash runway extended into the second half of 2028, supporting EDIT-401 advancement.
Price Impact
More from EDIT